

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Graham Nigel Maw, et al. :

APPLICATION NO.: Not Yet Assigned : Examiner:

FILING DATE: Herewith : Group Art Unit:

TITLE: Compounds for the Treatment of Female Sexual :
Dysfunction

Hon. Commissioner for Patents
Washington, D.C. 20231

Sir:

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s). The references for this application can be found in the parent case U.S. Non-Provisional Application No. 09/708,392.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a).

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

A prompt and favorable response is earnestly solicited.

Date: October 15, 2003

Respectfully submitted,

Arlene K. Musser

Arlene K. Musser
Attorney for Applicant(s)
Reg. No. 37,895

Pfizer Inc.
Patent Department, MS 8260-1611
Eastern Point Road
Groton, Connecticut 06340
(860) 715-0871

EXPRESS MAIL NO. EV 398059916 US

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>									ATTY. DOCKET NO. PC10343C			SERIAL NO. Not Yet Assigned					
									APPLICANT Graham Nigel Maw, et al.								
									FILING DATE Herewith						GROUP		
U.S. PATENT DOCUMENTS																	
EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE				
	US	4	6	6	6	9	0	8	5/19/87	Hamilton	514	229					
	US	5	5	7	4	0	6	8	11/12/96	Stamler, et al.	514	562					
	US	5	9	8	1	5	2	7	11/9/99	Daugan, et al.	514	290					
	US	5	8	6	1	3	9	6	1/19/99	Niewohner, et al.	514	234.2					
	US	5	6	1	2	3	1	4	3/18/97	Stamler, et al.	514	13					
	US	6	0	4	3	2	5	2	3/28/00	Bombrun	514	292					
	US	6	2	9	4	5	5	0	9/25/01	Place, et al.	514	302					
	US	6	3	1	6	4	5	7	11/13/01	Garvey, et al.	514	263					
	US	6	3	0	6	8	4	1	10/23/01	Place, et al.	514	149					
FOREIGN PATENT DOCUMENTS																	
DOCUMENT NUMBER									DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION				
													YES	NO			
	EP	0	9	1	1	3	3	3	4/24/99	European	C07D	487/04					
	EP	0	7	7	1	7	9	9	7/5/97	European	C07D	473/00					
	EP	0	2	7	4	4	3	4	7/13/88	European	C07D	409/06					
	WO	9	1	0	4	0	4	2	4/4/91	International	A61K	37/02					
	WO	9	7	2	0	8	2	1	6/12/97	International	C07D	239/95					
	WO	9	7	3	5	9	8	9	10/2/97	International	C12N	15/55					
	WO	9	7	3	9	7	6	0	10/30/97	International	A61K	33/26					
	WO	9	8	0	3	4	9	2	1/29/98	International	C07D	295/18					
	WO	9	9	2	0	2	6	6	4/29/99	International	A61K	31/19					
	WO	9	9	2	1	5	6	2	5/6/99	International	A61K	31/557					
	WO	9	9	2	2	7	3	1	5/14/99	International	A61K	31/44					
	WO	0	0	1	5	6	3	9	3/23/00	International	C07D	471/04					
	WO	0	0	1	5	2	2	8	3/23/00	International	A61K	31/4985					
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)																	
Traish, A., Moreland, R. B., Huang, Y., et al., <i>Mol. Cell Biol. Res. Comm.</i> , 2, 131-137 (1999).																	

EXPRESS MAIL NO. EV 39805991625

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)			ATTY. DOCKET NO. PC10343C	SERIAL NO. Not Yet Assigned
			APPLICANT Graham Nigel Maw, et al.	
			FILING DATE Herewith	GROUP
			Palle, Bredkjaer, Ottesen and Fahrenkrug 1990 Clinical and Experimental Pharmacology and Physiology vol 17, 61-68.	
			Beavo JA and Reifsnnyder DH, <i>Trends Pharmacol. Sci.</i> 11:150 (1990).	
			Wieshaar RE et al., <i>J. Med. Chem.</i> , 28, 537 (1985).	
			Giembycz MA, <i>Biochem. Pharm.</i> , 43:2041 (1992).	
			Lowe JA and Cheng JB, <i>Drugs for the Future</i> , 17, 799-807 (1992).	
			Ashur-Fabian, O., Perl, O., Lilling, G., et al., "SNV, a lipophilic superactive VIP analog, acts through cGMP to promote neuronal survival," <i>Peptides</i> , 20, 629-633 (1999).	
			Berman, J.R., Berman, L. & Goldstein, I., "Female sexual dysfunction: Incidence, pathophysiology, evaluation, and treatment options," <i>Urology</i> , 54, 385-391 (1999).	
			Berman, J., Goldstein, I., Werbin, T. et al., "Double blind placebo controlled study with crossover to assess effect of sildenafil on physiological parameters of the female sexual response," <i>J. Urol.</i> , 161, 805 (1999)	
			Burnett, A, Calvin, D., Silver, R. et al. "Immunohistochemical description of nitric oxide synthase isoforms in human clitoris," <i>J. Urol.</i> , 158, 75-78 (1997).	
			<i>Diagnostic and statistical manual of mental disorders-IV</i> , American Psychiatric Association: Washington, DC., pp. 493-518 (1987).	
			Fan, Y.P., Chakder, S & Ratton, S., "Inhibitory effect of zinc protoporphyrin IX on lower esophageal sphincter smooth muscle relaxation by vasoactive intestinal polypeptide and other receptor agonists," <i>J. Pharmacol. Exp. Ther.</i> , 285, 468-474 (1998).	
			Foda, H.D., Sharaf, H.H. Absood, A. et al., "Pituitary adenylate cyclase-activating peptide (PACAP), a VIP-like peptide, has prolonged airway smooth muscle relaxant activity," <i>Peptides</i> , 16, 1057-1061 (1995).	
			Frank, E., Anderson, C. & Rubinstein, D. "Frequency of sexual dysfunction in "normal" couples," <i>N. Engl. J. Med.</i> , 229, 111-115 (1978).	
			Goldstein, I. & Berman, J.R. "Vasculogenic female sexual dysfunction: vaginal engorgement and clitoral erectile insufficiency syndromes," <i>Int. J. Impot. Res.</i> , 10, S84-S90 (1998).	
			Gu, Z.F., Jensen, R.T. & Maton, P.N. "A primary role for protein kinase A in smooth muscle relaxation induced by adrenergic agonists and neuropeptides," <i>Am J. Physiol.</i> , 263, G360-G364 (1992).	
			Hauser-Kronberger, C., Cheung, A., Hacker, G. et al., "Peptidergic innervation of the human clitoris," <i>Peptides</i> , 20, 539-543 (1999).	
			Hoyle, C.H.V., Stones, R.W., Robson, T. et al., "Innervation of vasculature and microvasculature of the human vagina by NOS and neuropeptide containing nerves," <i>J. Anat.</i> , 188, 633-644 (1996).	
			Ingenhoven, N. & Beck-Sickinger, A.G. "Flourescent labelled analogues of neuropeptide Y for the characterisation of cells expressing NPY receptor subtypes," <i>J. Recept. Signal Transduct. Res.</i> , 17, 407-418 (1997).	
			Jovanovic, A., Jovanovic, S., Tulic, I. et al., "Predominant role for nitric oxide in the relaxation induced by vasoactive intestinal polypeptide in human uterine artery," <i>Mol. Human Reprod.</i> , 4, 71-76 (1998).	
			Kaplan, S.A., Reis, R.B., Kohm, I.J. et al., "Safety and efficacy of sildenafil in postmenopausal women with sexual dysfunction," <i>Urology</i> , 53, 481-486 (1999).	
			Kim, Y.C., Choi, H.K., Ahn, Y.S., et al. "The effect of vasoactive intestinal polypeptide (VIP) on rabbit cavernosal smooth muscle contractility," <i>J. Androl.</i> , 15, 392-397 (1994).	
			Laan, E. & Everaerd, W. "Physiological measures of vaginal vasocongestion," <i>Int. J. Impot. Res.</i> , 10, S107-S110 (1998).	
			Leiblum, S.R. "Definition and classification of female sexual disorders," <i>Int. J. Impotence Res.</i> , 10, S104-S106 (1998).	

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)			ATTY. DOCKET NO. PC10343C	SERIAL NO. Not Yet Assigned
			APPLICANT Graham Nigel Maw, et al.	
			FILING DATE Herewith	GROUP
			Levin, R.J., "The physiology of sexual function in women," <i>Clin. Obstet. Gynecol.</i> , 7, 213-252 (1980).	
			Levin, R.J., "VIP, vagina, clitoral and preurethral glans: An update on female genital arousal," <i>Exp. Clin. Endocrinol.</i> , 98, 61-69 (1991).	
			Levin, R.J., "The mechanisms of human female sexual arousal," <i>Ann. Rev. Sex Res.</i> , 3, 1-48 (1992).	
			Levin, R.J., & Wagner, G.) "TRH and vaginal blood flow-effects in conscious women and anaesthetized sheep," <i>J. Physiol.</i> , 378, 83P (1986)	
			Lundberg, J.M., Modin, A. & Malmstrom, R.E. "Recent developments with neuropeptide Y receptor antagonists," <i>Trends. Pharmacol. Sci.</i> , 17, 301-304 (1996).	
			Ottesen, B., Gerstenberg, T. Ulrichsen, H. et al., "Vasoactive intestinal oplypeptide (VIP) increases vaginal blood flow and inhibits smooth muscle activity in women," <i>Eur. J. Clin. Invest.</i> , 13, 321-324 (1983).	
			Ottesen, B., Wagner, G & Fahrenkrug, J., <i>Peptide innervation of the sexual organs</i> . In: Handbook of Sexology, Vol. 6, The Pharmacological and Endocrinology of Sexual Function, Sitsen, J.M.A. (eds), Amsterdam: Elsevier Science Publishers, chapter 4, pp 66-97. (1988).	
			Ottensen, B. Pedersen, B., Nielsen, J. et al., "Vasoactive polypeptide (VIP) provokes vaginal lubrication in normal women," <i>Peptides</i> , 8, 797-800 (1987).	
			Park, K., Goldstein, I., Andry, C., et al., "Vasculogenic female sexual dysfunction: The hemodynamic basis for vaginal engorgement insufficiency and clitoral erectile insufficiency," <i>Int. J. Impotence Res.</i> , 9, 27-37 (1997).	
			Rosen, R. Taylor, J., Leiblum, S. et al., "Prevalence of sexual dysfunction in women: results of a survey of 329 women in an outpatient gynecological clinic," <i>J. Sex Marital Ther.</i> , 19, 171-188 (1993).	
			Schiavi, R.C. & Seagraves, R.T., "The biology of sexual function," <i>Psychiat. Clin. North. Am.</i> , 18, 7-23 (1995).	
			Schoeffter, P. & Stoclet, J.C., "Effect of vasoactive intestinal polypeptide (VIP) on cyclic AMP level and relaxation in rat isolated aorta," <i>Eur. J. Pharmacol.</i> , 109, 275-279 (1985).	
			Serradeil-Le Gal, C., Valette, G., Rouby, P.E. et al., "SR 120819A, an orally-active and selective neuropeptide Y Y1 recptor antagonist," <i>FEBS Letters</i> , 3, 192-196 (1995).	
			Sjoberg, I. "The vagina: Morphological, functional and ecological aspects," <i>Acta Obst. Gynecol. Scand.</i> , 71, 84-85 (1992).	
			Spector, I.P. & Carey, M.P. "Incidence and prevalence of sexual dysfunctions: a critical review of the empirical literature," <i>Arch. Sex. Behav.</i> , 19, 389-408 (1990).	
			Wagner, G. "Aspects of genital physiology and pathology," <i>Sem. Neurol.</i> , 12, 87-97 (1992).	
			Werbin, T., Salimpour, P., Berman, L., et al., "Effect of sexual stimulation and age on genital blood flow in women and sexual stimulation," <i>J. Urol.</i> , 161, 688 (1999).	
			Wincze, J.P., Albert, a. & Bansal, S. "Sexual arousal in diabetic females: Physiological and self-report measures," <i>Arch. Sex Behav.</i> , 22, 587-601 (1993).	
			Wieland, H.A., Willim, K.D., Entzeroth, M. et al., "Subtype selectivity and antagonist profile of the nonpeptide Y1 receptor antagonist BIBP 3226," <i>J Pharmacol Exp Ther.</i> , 275, 143-9 (1995).	
			Ottesen, B. <u>American Journal of Obstetrics & Gynecology</u> , "Vasoactive Intestinal Peptide as a Neurotransmitter in the Female Genital Tract", Volume 147, pages 208-224 (1983)	
			Clark, J.T., et al., <u>Endocrinology</u> , "Neuropeptide Y Stimulates Feeding But Inhibits Sexual Behavior in Rats", Volume 117, No. 6., pages 2435-2442 (1985)	
			Suzuki, H., et al., <u>American Journal of Physiology</u> , "Neutral Endopeptidase Modulates VIP-induced Vasodilation In Hamster Cheek Pouch Vessels in Situ", Volume 271, No. 2, Part. 2, pages R393-R397 (1996)	
			Erdos, E.G., et al., <u>Laboratory Investigation</u> , "Neutral Metalloendopeptidase In Human Male Genital Tract", Volume 52, No. 4, pages 737-747 (1985)	

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>			ATTY. DOCKET NO. PC10343C	SERIAL NO. Not Yet Assigned
			APPLICANT Graham Nigel Maw, et al.	
			FILING DATE Herewith	GROUP
			United States Non-Provisional Patent Application No. 09/708,344, filed November 8, 2000; Maw, et al., "Compounds for the Treatment of Female Sexual Dysfunction", (Our Docket No. PC10931A)	
			United States Non-Provisional Patent Application No. 09/708,365, filed November 8, 2000; Maw, et al., "Compounds for the Treatment of Female Sexual Dysfunction", (Our Docket No. PC10932A)	
			United States Non-Provisional Patent Application No. 09/708,393, filed November 8, 2000; Maw, et al., "Compounds for the Treatment of Female Sexual Dysfunction", (Our Docket No. PC10930A)	
			Hedlund, et al., <u>PNASu</u> , "Erectile Dysfunction in Cyclin GMP-Dependent Kinase I-Deficient Mice", Volume 97, No. 5, pages 2349-2354 (2000)	
			U.S. 2002-0052370, filed April 02; Barber, et al., 514/237.5	
			U.S. 2002-0169101, filed November 2002; Gonzalez, et al., 514/1	
			US 2002/0028846	
			US2001/0051656	
			US2002/0019405	
EXAMINER			DATE CONSIDERED	

Conforms with FORM PTO-FB-A820

INFORMATION DISCLOSURE